NCT02502903View on ClinicalTrials.gov

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders

PHASE1CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

July 13, 2015

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Bullous Pemphigoid (BP)Cold Agglutinin Disease (CAD)Warm Autoimmune Hemolytic Anemia (WAIHA)End-stage Renal Disease (ESRD)
Interventions
DRUG

BIV009

OTHER

Placebo

Trial Locations (1)

1090

Medical University of Vienna, Vienna

Sponsors
All Listed Sponsors
collaborator

Celerion Clinical Research GmbH

UNKNOWN

collaborator

Assign Data Management and Biostatistics GmbH

OTHER

collaborator

ABF Pharmaceutical Services GmbH

INDUSTRY

collaborator

Quest Diagnostics-Nichols Insitute

INDUSTRY

collaborator

Covance

INDUSTRY

collaborator

PPD Laboratories - Virginia

UNKNOWN

collaborator

Softworld Inc. - Cambridge, MA

UNKNOWN

lead

Bioverativ, a Sanofi company

INDUSTRY